Medication Abortion Using Mifepristone and Misoprostol

  • Justine Wu


Half of all pregnancies in the United States are unintended, and half of these pregnancies end in elective termination [1]. At current abortion rates, a woman has a 43% chance of having an abortion by the age of 45 [2]. Despite the demand for abortion services, 87% of all counties in the United States have no abortion provider [3]. Furthermore, the majority of women seek abortion services at nonprimary care sites, disrupting continuity of care for those who would prefer to access abortion service from their primary care provider. Almost 90% of all abortions occur in the first trimester, when safe, simple, and highly effective abortion services can be provided in the primary care setting [3]. If primary care clinicians were to offer abortion care, they could greatly improve timely access to safe abortion and relevant reproductive health services, particularly in rural and underserved settings.


Ectopic Pregnancy Emergency Contraception Medication Abortion Abortion Service Last Menstrual Period 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Finer L, Henshaw K. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 2006;38(2):90–96.PubMedCrossRefGoogle Scholar
  2. 2.
    Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perspect 1998;30(1):24–29, 46.PubMedCrossRefGoogle Scholar
  3. 3.
    Finer LB, Henshaw SK. Abortion incidence and services in the United States in 2000. Perspect Sex Reprod Health 2003;35(1):6–15.PubMedCrossRefGoogle Scholar
  4. 4.
    Schaff EA, Fielding SL, Westhoff C, Ellertson C, Eisinger SH, Stadalius LS, Fuller L. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial. JAMA 2000;284(15):1948–1953.PubMedCrossRefGoogle Scholar
  5. 5.
    World Health Organisation Task Force on Post-ovulatory Methods of Fertility Regulation. Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. BJOG 2000;107(4):524–530.CrossRefGoogle Scholar
  6. 6.
    Bartley J, Brown A, Elton R, Baird DT. Double-blind randomized trial of mifepristone in combination with vaginal gemeprost or misoprostol for induction of abortion up to 63 days gestation. Hum Reprod 2001;16(10):2098–2102.PubMedCrossRefGoogle Scholar
  7. 7.
    Hamoda H, Ashok PW, Flett GM, Templeton A. A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation. BJOG 2005;112(8):1102-1108.PubMedCrossRefGoogle Scholar
  8. 8.
    Middleton T, Schaff E, Fielding S, Scahill M, Shannon C, Westheimer E, Wilkinson T, Winikoffet B. Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period. Contraception 2005;72:328–332.PubMedCrossRefGoogle Scholar
  9. 9.
    Creinin M, Fox M, Teal S, Chen A, Schaff E, Meyn L, for the MOD Study Trial. A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion. Obstet Gynecol 2004;103(5):851–859.PubMedCrossRefGoogle Scholar
  10. 10.
    Tang OS, Chan C, Ng E, Lee S, Ho PC. A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation. Hum Reprod 2003;18(11):2315–2318.PubMedCrossRefGoogle Scholar
  11. 11.
    Danco Laboratories, LLC. Mifeprex® Medication Guide. NY, NY: [updated 7/19/05, cited 10/30/07]. Available from:
  12. 12.
    Ellertson C, Elul B, Ambardekar S, Wood L, Carroll J, Coyaji K. Accuracy of assessment of pregnancy duration by women seeking early abortions. Lancet 2000;355:877–881.PubMedCrossRefGoogle Scholar
  13. 13.
    Fielding SL, Schaff EA, Nam NY. Clinicians’ perception of sonogram indication for mifepristone abortion up to 63 days. Contraception 2002;66:27–31.PubMedCrossRefGoogle Scholar
  14. 14.
    Clark WH, Gold M, Grossman D, Winikoff B. Can mifepristone abortion be simplified? A review of the evidence and questions for future research. Contraception 2007;75:245–250.PubMedCrossRefGoogle Scholar
  15. 15.
    Clark WH, Panton T, Hann L, Gold M. Medication abortion employing routine sequential measurement of serum hCG and sonography only when indicated. Contraception 2007;75(2):131–135.PubMedCrossRefGoogle Scholar
  16. 16.
    World Health Organization. Safe abortion: technical and policy guidance for health systems. Geneva: WHO, 2003.Google Scholar
  17. 17.
    Aldape MJ, Bryant AE, Stevens DL. Clostridium sordelli infection: epidemiology, clinical findings, and current perspectives on diagnosis and treatment. Clin Infect Dis 2006;43:1436–1446.PubMedCrossRefGoogle Scholar

Additional Resources Websites

  1. To obtain the Mifeprex® Medication Guide and Patient Agreement Form, visit:
  2. For patient and clinician resources regarding early abortion care (including the methotrexate/misoprostol regimen), visit The Reproductive Health Access Project:
  3. For information regarding abortion training in family medicine residencies, visit The Center for Reproductive Health Education in Family Medicine:
  4. For educational resources and a clinical curriculum regarding medication abortion, visit The National Abortion Federation:
  5. For information regarding state laws on abortion, visit The Center for Reproductive Rights:

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Family MedicineUniversity of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical SchoolNew BrunswickUSA

Personalised recommendations